Dentists in Livingston, CA Accepting Medicare
6 Dentists found. Showing 1 - 6
 Dr. Valerie Itzel Solano, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 600 B St Bldg A-c, Livingston, CA 95334 Phone: 661-600-7020 |
 Jeffrey Michael Carter, DDS Dentist Medicare: Medicare Enrolled Practice Location: 1112 Main St, Livingston, CA 95334 Phone: 209-862-3003 |
Dr. Gurjot Kaur Saini, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 600 B St, Livingston, CA 95334 Phone: 833-850-3500 |
Dr. Taranvir Kaur Cheema Dentist Medicare: Medicare Enrolled Practice Location: 600 B St, Livingston, CA 95334 Phone: 209-850-3500 |
Dr. Ruth Elizabeth Cabral-teixeira, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1112 Main St, Livingston, CA 95334 Phone: 209-394-8383 |
Alejandra Carolina Rodriguez Licea Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 706 Main St, Livingston, CA 95334 Phone: 209-535-9933 |
News Archive
Use of aconitine may lead to severe poisoning, warns Chinese physicians report
Chinese physicians report on the case of a woman who presented with aconitine-induced cardiovascular symptoms. Their report, published in the Canadian Journal of Cardiology, warns that the use of this natural ingredient may lead to severe poisoning.
Testosterone replacement therapy associated with increased risk of stroke, heart attack
Aging men with low testosterone levels who take testosterone replacement therapy are at a slightly greater risk of experiencing an ischemic stroke, transient ischemic attack, or myocardial infarction, especially during the first two years of use, reports a study appearing in The American Journal of Medicine, published by Elsevier.
Routine mammograms can show arterial calcium deposits in women with ESRD, CKD
Routine mammograms performed for breast cancer screening could serve another purpose as well: detecting calcifications in the blood vessels of patients with advanced kidney disease, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.
CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer
Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.
› Verified 9 days ago